Xeris Biopharma Holdings, Inc. XERS Accrued Expenses
Accrued Expenses at other companies
Other financials
Where this comes from
Reported directly by Xeris Biopharma Holdings, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OtherLiabilitiesCurrent.
The official record: Xeris Biopharma Holdings, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Xeris Biopharma Holdings, Inc.'s accrued expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Xeris Biopharma Holdings, Inc.'s accrued expenses?
- Xeris Biopharma Holdings, Inc. (XERS) reported accrued expenses of $4.35M in Q1 2026.
- How has Xeris Biopharma Holdings, Inc.'s accrued expenses changed year-over-year?
- Xeris Biopharma Holdings, Inc.'s accrued expenses increased by 2690.4% year-over-year, from $156K to $4.35M.
- What is the long-term trend for Xeris Biopharma Holdings, Inc.'s accrued expenses?
- Over 5 years (2020 to 2025), Xeris Biopharma Holdings, Inc.'s accrued expenses has grown at a 72.3% compound annual growth rate (CAGR), from $322K to $4.89M.
- What does accrued expenses mean?
- Expenses incurred but not yet paid or invoiced — interest accruals, tax accruals, warranty reserves, and other timing differences.